



Inbal Zafir-Lavie, Bio

Dr. Zafir-Lavie has completed her PhD, cum laude, in 2010 the Technion – Israel Institute of Technology, in antibody engineering and cancer immunology. Upon completing her PhD, Dr. Zafir-Lavie worked at Bio-Rad as project leader in Protein Technologies Unit.

In 2013 Dr. Zafir-Lavie joined Aevi Genomic Medicine as a team leader for the development of antibody gene-therapy platform and later as Israel R&D Site Head. Later on, she relocated to Philadelphia, PA USA to work as a Senior Scientist in translational medicine group at Aevi Genomic Medicine, collaborating with Center of Applied Genomics at CHOP. In her work in the US, Dr. Zafir-Lavie has developed an innovative diagnostic assay for an auto-immune disease and supported biological drugs projects towards IND and clinical trials.

Upon returning from the USA, Dr. Zafir-Lavie has worked for Merck group as a senior scientist where she was responsible for transferring innovative projects from the academy to the industry towards IND.

At 2020 Inbal joined Gina-Life Diagnostics as CEO and co-founder, she has been leading the company ever since.

Inbal is an expert in immunology, biomarkers and antibody engineering. She brings vast experience in developing diagnostic assays and bringing biological drugs to IND and clinical trials.

Through her career Dr. Zafir-Lavie is seeking to promote translational work, which prolong patients' life. Dr. Zafir-Lavie is keen to promote technologies for improving women's health.